
Join to view full profile
3036 NE Martin Luther King Jr BlvdPortland, OR 97212
Dr. Turner is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Erick Turner, Professor Emeritus at the Oregon Health & Science University (OHSU), is a psychiatrist with an extensive background in both clinical and academic settings. After completing his medical education at OHSU, he did his psychiatry residency at the University of California, Irvine, and a research fellowship at the National Institute of Mental Health (NIMH). He then worked as a Medical Officer at the FDA, reviewing applications submitted by pharmaceutical companies to determine whether their drugs were sufficiently safe and effective to be approved for the US market. Inspired by what he learned inside the proverbial ‘sausage factory’, his research has focused on publication bias and on the evolution in FDA approval standards. Several of his publications have been very widely cited, most notably a 2008 paper in the NEJM on the selective publication of antidepressant trials. In parallel with his academic career, he has worked as an outpatient psychiatrist at a Veterans Affairs Medical Center and, more recently, part-time at Cascadia Health.
Education & Training
National Institutes of Health Clinical CenterResidency, Psychiatry, 1992 - 1998
University of California (Irvine)Residency, Psychiatry, 1989 - 1992
Oregon Health and Science University School of MedicineClass of 1989
Certifications & Licensure
OR State Medical License 2023 - 2027
MD State Medical License 1993 - 2025
CA State Medical License 1990 - 1992
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- Assessing Drug Efficacy After Multiple Negative Trials-Gepirone's Journey Through the FDA.Erick H Turner, John H Powers 3rd, Rosa Y Ahn-Horst, Aaron S Kesselheim
JAMA Psychiatry. 2026-08-01 - 2 citationsEfficacy and safety of esketamine for "treatment resistant depression": registered report for a systematic review with an individual patient data meta-analysis of rand...Florian Naudet, Claude Pellen, Liviu A Fodor, Chiara Gastaldon, Corrado Barbui
BMC Medicine. 2025-11-28 - 6 citationsEnding publication bias: A values-based approach to surface null and negative results.Stephen Curry, Eunice Mercado-Lara, Virginia Arechavala-Gomeza, C Glenn Begley, Christophe Bernard
Plos Biology. 2025-09-01
Press Mentions
How a Drug with More Negative Than Positive Studies Won FDA ApprovalJune 24th, 2026
An Old-but-New Treatment for Opioid AddictionApril 2nd, 2021- What to Do When Pandemic Stress Meets Seasonal Depression Caused by Lack of LightOctober 13th, 2020
Professional Memberships
- American Society of Clinical PsychopharmacologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:








